Visus in the limelight

As an active clinical-stage pharmaceutical company on the leading-edge of ophthalmic innovations, we’re bound to be making headlines. Check back often for the very latest updates, announcements, and breakthroughs that are propelling us forward.

Discover our pipeline today.

With officies in Seattle and Orange County, Visus is home to our lead clinical candidate, BRIMOCHOL™ (carbachol + brimonidine tartrate), an eye drop being evaluated to correct the loss of near vision associated with presbyopia.

Visus in the limelight

As an active, clinical-stage company on the leading-edge of ophthalmic innovation, we’re bound to be making headlines. Check back often for the very latest updates, announcements, and breakthroughs that are propelling us forward.

Discover our pipeline today.

With officies in Seattle and Orange County, Visus is home to our lead clinical candidate, BRIMOCHOL™ (carbachol + brimonidine tartrate), an eye drop being evaluated to correct the loss of near vision associated with presbyopia.

News

CORPORATE PROFILE

Visus Therapeutics is a clinical-stage company in pursuit of developing the the world's first presbyopia-correcting eye drop with the potential to last at least eight hours.
‍
With offices in Seattle, Washington, and Orange County, California, our lead clinical candidate is BRIMOCHOL™ (carbachol + brimonidine tartrate), an eye drop being evaluated to correct the loss of near vision associated with presbyopia. In parallel, Visus Therapeutics is focused on advancing its pipeline of early-stage ophthalmic product candidates.

Media contact: media@visustx.com

Visus Therapeutics is a clinical-stage company focused on developing innovative ophthalmic therapies to improve vision for people around the world. Our pipeline of early-stage ophthalmic product candidates includes applications in ocular surface disease, glaucoma, and age-related macular degeneration.

LiveStreaming Event

View our August 31st Capital Markets Day Presentation here.

Featured NEWS

Press Release

May 11, 2022

Visus Therapeutics, Inc., and Zhaoke Ophthalmology Limited Announce Exclusive Licensing Agreement to Commercialize BRIMOCHOL™ PF and Carbachol PF in Greater China, South Korea and Select Southeast Asian Markets for the Treatment of Presbyopia

Visus Therapeutics, Inc., and Zhaoke Ophthalmology Limited Announce Exclusive Licensing Agreement to Commercialize BRIMOCHOL™ PF and Carbachol PF in Greater China, South Korea and Select Southeast Asian Markets for the Treatment of Presbyopia

News Article

March 9, 2021

Visus Therapeutics Gathers $36 Million to Develop Presbyopia Drug

Visus Therapeutics Gathers $36 Million to Develop Presbyopia Drug

Press Releases

May 11, 2022

Visus Therapeutics, Inc., and Zhaoke Ophthalmology Limited Announce Exclusive Licensing Agreement to Commercialize BRIMOCHOL™ PF and Carbachol PF in Greater China, South Korea and Select Southeast Asian Markets for the Treatment of Presbyopia

Visus Therapeutics, Inc., and Zhaoke Ophthalmology Limited Announce Exclusive Licensing Agreement to Commercialize BRIMOCHOL™ PF and Carbachol PF in Greater China, South Korea and Select Southeast Asian Markets for the Treatment of Presbyopia

April 27, 2022

Visus Therapeutics Announces New Scientific Data to Be Presented During the 2022 ARVO Annual Meeting

Visus Therapeutics Announces New Scientific Data to Be Presented During the 2022 ARVO Annual Meeting

March 22, 2022

Visus Therapeutics Initiates Phase 3 Pivotal Trials of BRIMOCHOL™ PF for the Treatment of Presbyopia

Visus Therapeutics Initiates Phase 3 Pivotal Trials of BRIMOCHOL™ PF for the Treatment of Presbyopia

March 16, 2022

Visus Therapeutics Announces Appointment of Eye Care Industry Veteran Julia Williams as Vice President of Clinical and Medical Affairs and Expansion of Irvine Co-Headquarters

Visus Therapeutics Announces Appointment of Eye Care Industry Veteran Julia Williams as Vice President of Clinical and Medical Affairs and Expansion of Irvine Co-Headquarters

News Articles

March 23, 2022

Visus Initiates Phase 3 Trial of Brimochol PF to Treat Presbyopia

Visus Initiates Phase 3 Trial of Brimochol PF to Treat Presbyopia

February 16, 2022

The Latest Roundup of Key Presbyopia–Correcting Drops

The Latest Roundup of Key Presbyopia–Correcting Drops

January 5, 2022

Top Life Sciences Startups to Watch in 2022

Top Life Sciences Startups to Watch in 2022

December 8, 2021

Visus closes in on AbbVie with midphase data on long-sightedness eye drop

Visus closes in on AbbVie with midphase data on long-sightedness eye drop